Hpv-Specific Risk Management in Cervical Pathology Screening and Comparison of Pathological Results

Year 2023, , 775 - 778, 31.12.2023

Sıtkı Özbilgeç , Şeyma Çiçek , Tuğçehan Şimşekler , Fatih Akkuş , Emine Türen Demir , Ali Acar

https://doi.org/10.54005/geneltip.1340317

Abstract

Background: In the process of detecting cervical cancer, cytology and HPV genotype screening both play a significant part. More researches are required to determine whether or not multiple HPV genotyping can accurately predict cytological abnormalities.
Methods: A total of 696 female individuals were subjected to analysis for cytology and HPV genotype testing. HPV-DNA, smear and final pathology results of these patients and the relationship between them were investigated using statistical methods.
Results: Cytological data indicating abnormalities were seen in a total of 110 subjects. HPV-16 was determined to be the most prevalent variety among the patients, and HPV-16-positive females were found to have an elevated risk of cervical lesions. HPV 16 infection rates were substantially increased in patients with HSIL and higher lesions.
Conclusion: An infection caused by HPV-16 is a major risk factor for cervical lesions. A test that examines many HPV genotypes may be able to predict cytological problems.

Keywords

HPV, Smear, Cervical Screening, Cervical Preinvasive Lesions, Cervical Cancer

Servikal Patoloji Taramasında Hpv’ye Özgü Risk Yönetimi ve Patoloji Sonuçlarının Karşılaştırılması

Abstract

Arka plan: Serviks kanserinin saptanması sürecinde sitoloji ve HPV genotip taramasının her ikisi de önemli bir rol oynamaktadır. Çoklu HPV genotiplemesinin sitolojik anormallikleri doğru bir şekilde tahmin edip edemeyeceğini belirlemek için daha fazla araştırma yapılması gerekmektedir.
Yöntemler: Toplam 696 kadın birey sitoloji ve HPV genotip testi için analize tabi tutulmuştur. Bu hastaların HPV-DNA, smear ve nihai patoloji sonuçları ve aralarındaki ilişki istatistiksel yöntemler kullanılarak araştırılmıştır.
Bulgular: Toplam 110 olguda anormallik gösteren sitolojik veriler görüldü. HPV-16’nın hastalar arasında en yaygın çeşit olduğu ve HPV-16-pozitif kadınlarda servikal lezyon riskinin yüksek olduğu bulunmuştur. HPV 16 enfeksiyon oranları HSIL ve daha yüksek lezyonlu hastalarda önemli ölçüde artmıştır.
Sonuç: HPV-16’nın neden olduğu bir enfeksiyon servikal lezyonlar için önemli bir risk faktörüdür. Birçok HPV genotipine bakan bir test sitolojik sorunları öngörebilir.

Keywords

HPV, Smear, Servikal Tarama, Servikal Preinaziv Lezyonlar, Serviks Kanseri

References

• Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert review of vaccines. 2018;17(12):1085-91.
• Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P, et al. The IARC Perspective on Cervical Cancer Screening. The New England journal of medicine. 2021;385(20):1908-18.
• Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global health. 2020;8(2):e191-e203.
• WHO Guidelines Approved by the Guidelines Review Committee. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. Geneva: World Health Organization© World Health Organization 2021.; 2021.
• Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. The Lancet Global health. 2022;10(8):e1115-e27.
• Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24(2):102-31.
• Arbyn M, Simon M, de Sanjosé S, Clarke MA, Poljak M, Rezhake R, et al. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis. The Lancet Oncology. 2022;23(7):950-60.
• Salehi-Vaziri M, Sadeghi F, Hashemi FS, Haeri H, Bokharaei-Salim F, Monavari SH, et al. Distribution of Human Papillomavirus Genotypes in Iranian Women According to the Severity of the Cervical Lesion. Iranian Red Crescent medical journal. 2016;18(4):e24458.
• Arslan HN, Oruc MA. Results from a cervical cancer screening program in Samsun, Turkey. BMC women's health. 2022;22(1):331.
• Benoy IH, Vanden Broeck D, Ruymbeke MJ, Sahebali S, Arbyn M, Bogers JJ, et al. Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. American journal of obstetrics and gynecology. 2011;205(6):569.e1-7.
• Gultekin M, Dundar S, Keskinkilic B, Turkyilmaz M, Ozgul N, Yuce K, et al. How to triage HPV positive cases: Results of four million females. Gynecol Oncol. 2020;158(1):105-11.
• Dursun P, Ayhan A, Mutlu L, Çağlar M, Haberal A, Güngör T, et al. HPV types in Turkey: multicenter hospital based evaluation of 6388 patients in Turkish gynecologic oncology group centers. Turk patoloji dergisi. 2013;29(3):210-6.
• Li X, Xiang F, Dai J, Zhang T, Chen Z, Zhang M, et al. Prevalence of cervicovaginal human papillomavirus infection and genotype distribution in Shanghai, China. Virology journal. 2022;19(1):146.